Nanovis received FDA 510(k) clearance to market FortiCore® interbody fusion devices that feature a Nanosurface-enhanced porous titanium scaffold, intermolded with a PEEK core.
The devices are intended for use in transforaminal and anterior lumbar interbody fusion procedures (TLIF and ALIF). The nanopatterned surface is intended to target fixation-related complications; it also forms the basis of a bactericidal program under development to address infection-related complications
FortiCore devices received initial FDA clearance in 2014. Since then, over 4,250 units have been implanted; this is an increase from the milestone of the 2,000th implantation, noted in 1Q17.
Sources: Nanovis; ORTHOWORLD Inc.
Nanovis received FDA 510(k) clearance to market FortiCore® interbody fusion devices that feature a Nanosurface-enhanced porous titanium scaffold, intermolded with a PEEK core.
The devices are intended for use in transforaminal and anterior lumbar interbody fusion procedures (TLIF and ALIF). The nanopatterned surface is intended to target...
Nanovis received FDA 510(k) clearance to market FortiCore® interbody fusion devices that feature a Nanosurface-enhanced porous titanium scaffold, intermolded with a PEEK core.
The devices are intended for use in transforaminal and anterior lumbar interbody fusion procedures (TLIF and ALIF). The nanopatterned surface is intended to target fixation-related complications; it also forms the basis of a bactericidal program under development to address infection-related complications
FortiCore devices received initial FDA clearance in 2014. Since then, over 4,250 units have been implanted; this is an increase from the milestone of the 2,000th implantation, noted in 1Q17.
Sources: Nanovis; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
